CONMED (CNMD)
(Delayed Data from NYSE)
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment
by Zacks Equity Research
Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.
Varian Medical Buys Endocare & Alicon to Boost Cancer Care
by Zacks Equity Research
Varian Medical (VAR) expects the buyouts to prove accretive to bottom line in fiscal 2020.
HealthEquity (HQY) Earnings & Revenues Top Estimates in Q1
by Zacks Equity Research
Higher revenues, solid segmental performance and expansion in margins benefit HealthEquity's (HQY) Q1 earnings.
Cooper Companies (COO) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and expansion in margins benefit Cooper Companies' (COO) Q2 earnings.
Veeva Systems (VEEV) Q1 Earnings Top Estimates, View Strong
by Zacks Equity Research
Veeva Systems (VEEV) issues strong guidance for fiscal 2020.
NextGen's (NXGN) Q4 Earnings Top Estimates, Bookings Down Y/Y
by Zacks Equity Research
NextGen (NXGN) Q4 results benefit from better performing recurring segment. However, gross margin contraction remains a woe.
Here's Why You Should Consider Betting On CONMED Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.
Conmed (CNMD) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conmed (CNMD) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Conmed (CNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Globus Medical Reveals Positive Study Results for ExcelsiusGPS
by Zacks Equity Research
Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure
Can Segmental Growth Aid Cooper Companies' (COO) Q2 Earnings?
by Zacks Equity Research
Cooper (COO) expects to gain from CVI and CSI units in the fiscal second quarter.
New Strong Buy Stocks for May 24th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday:
Veeva Systems (VEEV) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Top-line growth and solid show by Subscription services and Professional services units are likely to aid Veeva Systems (VEEV) in Q1 earnings. However, rising expenses remains a dampener.
Medtronic (MDT) Q4 Earnings Beat, Operating Margin Rises
by Zacks Equity Research
Excluding the Diabetes group, Medtronic (MDT) displays better performances at CER on the back of growth in rest of the business segments and across all geographies.
Here's Why You Should Hold On to Integra LifeSciences Stock
by Zacks Equity Research
Investor confidence is still high on growth prospects of Integra LifeSciences (IART).
QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
by Zacks Equity Research
This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
by Zacks Equity Research
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.
Hologic Breast Health Arm Aids Strongly, Rising Costs Ail
by Zacks Equity Research
Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.
Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?
by Zacks Equity Research
Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.
ResMed Study Shows Remote Monitoring Benefits on CPAP Use
by Zacks Equity Research
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) benefits from launches like Halo ION.
Avedro (AVDR) Hits a 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Avedro (AVDR) gains from promising developments in recent times.
Varian Medical's CTSI Buyout to Boost Oncology Services Unit
by Zacks Equity Research
The CTSI buyout is expected to prove accretive to Varian Medical's (VAR) adjusted earnings per share during fiscal 2021.
Why Should You Hold on to Myriad Genetics (MYGN) Stock?
by Zacks Equity Research
Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).
LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses
by Zacks Equity Research
LabCorp's (LH) diagnostics business grows organically despite additional price reductions.